Use of Low Molecular Weight Heparin in Covid-...

Use of Low Molecular Weight Heparin in Covid-19 Patients

Author Name : Injamamul Haque, Sazedur Rahman Akanda, Dr. Mohibul Hoque, Nayan Ranjan Ghosh Biswas, Azad Moidul Islam

ABSTRACT

Various organ-specific and systemic individual observations have been added by the COVID-19 pandemic, some previously notified in viral infections, including severe acute respiratory syndrome (SARS) and others that seem to be specific to SARS-corona virus (CoV)-2. The Corona virus disease 2019 (COVID-19) etiology is raising being observed where a high number of thrombotic episodes are being noted which is supported by various clotting indicators. Therefore, COVID-19 can be accepted as a blood clotting risk factor and as a clotting factor disorder. Guidelines for use of Heparin are run by increasingly developing information from scientific perceptions, autopsy-based results, and conclude from in-vitro and ex-vivo experiments and complex modeling; however, several issues remain unresolved and scientific trials that are need to be added to results in most fields not yet structured.

The following review conclusions emerging findings into pathobiology, mechanism(s), diagnosis, administration, scientific foundations, and planned or ongoing COVID-19-associated coagulopathy clinical trials and utilize of Heparin in COVID-19 patients.

Use of anticoagulant i.e. Heparin, distinguish higher-risk blood clotting patients, mostly the aged, those with symptomatology and high protein fragment levels is an essential step to prevent thromboembolism in COVID-19 patients.

KEYWORD: COVID-19, clotting risk factor, use of Heparin.